$VRTX · Vertex Pharmaceuticals

Healthcare / BiotechNDX100

EPS 0–0

DIR 0–0

MAE +3.4%

Latest call · 2026-05-04

✓ Scored · earnings 2026-05-04 AMC

The call

EPS

$4.30

BEAT· +2.4% vs street

Direction

🟢 UP

1d +2.5% · 3d +4.0%

Confidence

MEDIUM

Positioning: hype_washed_out

Spot at call

$427.93

as of 2026-05-04

Head-to-head · Claude vs the Street vs reality

	Claude	Street	Actual
EPS	$4.30	$4.20	—
Revenue	$3.05B	$2.98B	—
Direction (1d)	🟢 UP	🟢 UP 22B · 6H · 1S	🔴 DOWN
1d move	+2.5%	—	-0.9%
3d move	+4.0%	—	—

EPS — Direction Tie

Thesis

Cystic-fibrosis franchise stable while two new launches (Casgevy gene therapy, Journavx non-opioid pain) take baton from Trikafta. Last quarter's EPS miss has positioning cautious into the print — Most Accurate Estimate is below consensus, a classic washed-out setup. Edge is Journavx scripts ramping faster than buy-side models.

What would flip it

Trikafta U.S. softness repeats Q4's pattern and lifts the mix-shift overhang back into the foreground.

💡 Washed-out + new-narrative setup. Long into print sized small, add on initial pop confirmation.

The market's narrative

Cystic-fibrosis monopoly with two new launches (Casgevy, Journavx) pivoting the franchise away from single-drug concentration — but Q4 EPS miss + 'Most Accurate Estimate' below consensus has positioning leaning cautious.

Where the Street may be wrong

Journavx (suzetrigine) prescription volumes ramping faster than buy-side models since FDA-approved in Jan 2025 — first new chemical entity in non-opioid pain in a generation.
Casgevy cell-collection cadence has been quietly compounding into 2026; product infusions stepping up should drive a non-CF revenue contribution that reframes the diversification debate.

Peer read: AMGN +2.43% on 4/30 — LLY-halo pipeline-pull-forward template applies: clean print on biotech with new-narrative carve-out runs through hype_high

Reasoning

Trikafta/Kaftrio Q1 sales tracking ~$2.40B = base franchise stability intact, no LOE risk yet.
Casgevy + Journavx ramps are the 2026 P&L step-ups buy-siders are conservatively modeling.
Q4 EPS miss + Most Accurate Estimate $4.18 < consensus $4.20 = positioning is washed out, low bar.
RSI 42 + price below 50EMA $446.60 = technical setup pre-cleansed; mean-reversion fuel.
22 Buy / 6 Hold / 1 Sell with $555 PT = Street still constructive, awaiting catalyst to re-engage.

Risks to the call

Trikafta U.S. share continues to drift to ex-U.S. mix shift, masking domestic price weakness — Q1 print could MISS again like Q4.
Journavx commercial-payer gating remains uneven; if scripts look soft, the diversification thesis pushes back to 2H26.